NDASUBCUTANEOUSSOLUTIONPriority Review
Approved
May 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
Priority Review
MOUNJARO (tirzepatide) by Eli Lilly and Company is g-protein-linked receptor interactions [moa]. Approved for glucose-dependent insulinotropic polypeptide receptor agonist [epc]. First approved in 2022.
Drug data last refreshed 7m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MOUNJARO (tirzepatide) is a dual GIP/GLP-1 receptor agonist administered as a subcutaneous injection for the treatment of type 2 diabetes mellitus. It works via G-protein-coupled receptor interactions to enhance glucose-dependent insulin secretion and improve glycemic control. The drug represents a novel dual-mechanism approach to diabetes management.
$2.4BPart D
PeakGrowing
15.3 years to LOEMOUNJARO is at peak commercial maturity with $2.4B in Part D spending and 1.8M claims in 2023, indicating a large, established brand team supporting sustained growth.
Mechanism of Action
G-Protein-linked Receptor Interactions
Pharmacologic Class:
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Started Jan 2027
70 enrolled
Obesity
Tirzepatide for Treatment of CCCA
Started Sep 2026
20 enrolled
Central Centrifugal Cicatricial Alopecia (CCCA)
Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)
Started Sep 2026
20 enrolled
Pouch, IlealPouches, IleoanalBowel Diseases, Inflammatory
A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity
Started Sep 2026
18 enrolled
Diabetes Mellitus, Type 1OverweightObesity
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
Started Sep 2026
150 enrolled
Obesity
Worked on MOUNJARO at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.